High-intensity statins are the two strongest statin medications at their highest approved doses: atorvastatin (Lipitor) at 40 to 80 mg daily and rosuvastatin (Crestor) at 20 to 40 mg daily. These are the only two statins that qualify as high-intensity therapy, defined by their ability to lower LDL cholesterol by 50% or more.
The Two High-Intensity Statins and Their Doses
Only two of the seven available statins can achieve high-intensity cholesterol lowering. Every other statin, even at its maximum dose, falls into the moderate or low-intensity category.
- Atorvastatin (Lipitor): 40 to 80 mg per day
- Rosuvastatin (Crestor): 20 to 40 mg per day
The distinction matters because “high intensity” isn’t just a marketing label. It’s a clinical classification based on how much a drug lowers LDL cholesterol. Moderate-intensity statins lower LDL by 30% to 49%, while high-intensity statins clear that 50% threshold. Lower doses of atorvastatin (10 to 20 mg) and rosuvastatin (5 to 10 mg) are classified as moderate-intensity, so the dose you take determines the category, not just the drug name.
How They Work
All statins block the same enzyme in the liver, one that controls the rate of cholesterol production. When that enzyme is inhibited, liver cells sense they’re running low on cholesterol and respond by pulling more LDL out of the bloodstream. High-intensity doses simply push this process harder, forcing the liver to scavenge more circulating LDL particles than moderate or low doses can achieve.
In practice, not everyone hits that 50% reduction target. A large trial of rosuvastatin found that about 46% of participants achieved a 50% or greater drop in LDL, while another 43% saw a meaningful but smaller reduction. The people who reached that 50% mark had substantially better cardiovascular outcomes, with roughly 57% lower risk of major events compared to placebo.
Who Needs High-Intensity Therapy
Guidelines from the American College of Cardiology and American Heart Association identify several groups where high-intensity statins are the recommended starting point, not a step-up option.
The clearest case is anyone with LDL cholesterol at or above 190 mg/dL between ages 20 and 75. At that level, a high-intensity statin is recommended without even calculating an overall cardiovascular risk score. People who have already had a heart attack, stroke, or other atherosclerotic cardiovascular event are also candidates, and the most recent 2025 guidelines for acute coronary syndrome recommend starting a high-intensity statin during the hospital stay itself, often paired with an additional cholesterol-lowering medication.
For people with type 2 diabetes between ages 40 and 75, moderate-intensity therapy is the starting point, but doctors may escalate to high-intensity based on additional risk factors. The same applies to people whose 10-year cardiovascular risk falls in the intermediate range (7.5% to 20%), where risk-enhancing factors like family history or chronic kidney disease can tip the recommendation toward high-intensity treatment. Anyone with a 10-year risk of 20% or higher is generally a candidate for high-intensity therapy from the start.
Side Effects at Higher Doses
The most common concern with any statin is muscle pain, which affects a meaningful minority of users. At high-intensity doses, muscle-related side effects are somewhat more frequent. Rhabdomyolysis, a rare but serious form of muscle breakdown, occurs in about 4 per 10,000 people on high-intensity therapy compared to 2 per 10,000 on lower doses. That’s still uncommon, but it’s the reason your doctor will ask about unexplained muscle pain or weakness.
High-intensity statins also carry a slightly higher risk of developing type 2 diabetes. A meta-analysis of over 32,000 patients found that intensive dosing led to about 150 more diabetes cases compared to moderate dosing across the full study populations. Overall, statin use of any intensity raises diabetes risk by roughly 12%. For most people at high cardiovascular risk, the heart protection substantially outweighs this trade-off, but it’s worth knowing about, especially if you already have prediabetes or other metabolic risk factors.
What to Expect After Starting
After you begin a high-intensity statin or change your dose, your doctor will typically recheck your cholesterol with a fasting blood draw somewhere between 4 and 12 weeks later. This first follow-up confirms that the drug is working as expected and that you’re actually taking it consistently, since adherence is one of the biggest real-world reasons people don’t reach their LDL goals. After that initial check, lipid panels are usually repeated every 3 to 12 months depending on how stable your numbers are.
One important point from the latest guidelines: if your LDL drops very low on a high-intensity statin, that’s not a reason to reduce the dose. Current evidence considers very low LDL levels both safe and beneficial, and guidelines explicitly advise against scaling back therapy just because the numbers look good. The protection continues at lower LDL levels, and reducing the dose could undo that benefit.